新锐医药(06108)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06108 新锐医药

未开盘 10-12 15:57:56

0.230

+0.021

+10.05%

最高0.249	最低0.209	成交量98.88万
今开0.209	昨收0.209	日振幅19.14%
总市值4,623万	流通市值4,623万	总股本2.01亿
成交额23.38万	换手率0.49%	流通股本2.01亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06108","market":"HK","secType":"STK","nameCN":"新锐医药","latestPrice":0.23,"timestamp":1791791876826,"preClose":0.209,"halted":0,"volume":988800,"delay":0,"changeRate":0.10047846889952163,"floatShares":200999999,"shares":200999999,"eps":-0.1194,"marketStatus":"未开盘","change":0.021,"latestTime":"10-12 15:57:56","open":0.209,"high":0.249,"low":0.209,"amount":233750,"amplitude":0.191388,"askPrice":0.23,"askSize":96000,"bidPrice":0.226,"bidSize":8000,"shortable":0,"etf":0,"ttmEps":-0.081,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791855000000},"marketStatusCode":0,"adr":0,"listingDate":1382630400000,"exchange":"SEHK","adjPreClose":0.209,"openAndCloseTimeList":[[1791768600000,1791777600000],[1791781200000,1791792000000]],"volumeRatio":4.524158127985064,"lotSize":8000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06108","defaultTab":"news","newsList":[{"id":"1192342956","title":"新锐医药（06108）公布最新董事会及委员会成员名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1192342956","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192342956?lang=zh_cn&edition=full","pubTime":"2026-10-12 20:56","pubTimestamp":1791809781,"startTime":"0","endTime":"0","summary":"2026年10月12日，新锐医药国际控股有限公司发布公告，列明董事会成员及各专门委员会组成如下：。公告未披露其他财务数据或经营指标。本次信息披露完成后，公司董事会及其各委员会人员架构正式确立。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118222706","title":"新锐医药（06108）公告执董褚雪平辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=1118222706","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118222706?lang=zh_cn&edition=full","pubTime":"2026-10-12 20:41","pubTimestamp":1791808891,"startTime":"0","endTime":"0","summary":"新锐医药（06108）10月12日晚间公告称，自2026年10月12日起，因其他业务追求及承担，执行董事褚雪平先生辞去执行董事职务。  \n   \n公司表示，褚雪平已确认其与董事会并无意见分歧，且无任何与辞任有关的事项需提请股东或香港联合交易所有限公司注意。董事会对褚雪平在任内作出的贡献表示衷心感谢。  \n   \n公告同时披露，目前公司董事会成员包括：执行董事王秋勤女士（兼主席）及周湾女士；独立非执行董事梁志坚先生、李倩明女士及施礼贤先生。  \n   \n本公告由新锐医药国际控股有限公司于2026年10月12日在香港发布。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674702188","title":"新锐医药：褚雪平辞去执行董事职位","url":"https://stock-news.laohu8.com/highlight/detail?id=2674702188","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674702188?lang=zh_cn&edition=full","pubTime":"2026-10-12 20:40","pubTimestamp":1791808800,"startTime":"0","endTime":"0","summary":"南财智讯10月12日电，新锐医药（06108.HK）公告，褚雪平因其他业务追求及承担，辞任公司执行董事职务，自2026年10月12日起生效。褚雪平已确认与董事会无意见分歧，亦无与请辞有关的事项需提请公司股东或香港联合交易所有限公司垂注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610123892878962.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610123892878962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06108","BK1511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674187055","title":"新锐医药(06108.HK)：褚雪平辞任执董","url":"https://stock-news.laohu8.com/highlight/detail?id=2674187055","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674187055?lang=zh_cn&edition=full","pubTime":"2026-10-12 20:38","pubTimestamp":1791808733,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1511","06108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139533318","title":"新锐医药9月股份变动月报表维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1139533318","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139533318?lang=zh_cn&edition=full","pubTime":"2026-10-05 17:09","pubTimestamp":1791191340,"startTime":"0","endTime":"0","summary":"新锐医药国际控股有限公司于2026年10月5日发布了截至2026年9月30日止月份的股份变动月报表。根据公告，公司法定注册股本保持不变。截至本月末，已发行股份总数与上月底相比无变化，维持在200,616,665股，未持有任何库藏股份。本月报表由公司秘书吴日升签署。报告显示，公司继续遵守香港联交所《上市规则》及其他适用法律法规要求。截至2026年9月末，公司整体股本结构保持稳定，未有新增发行及回购活动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177727262","title":"新锐医药2026年上半年营收1.13亿港元，经调整净亏损356.50万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177727262","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177727262?lang=zh_cn&edition=full","pubTime":"2026-09-16 21:02","pubTimestamp":1789563766,"startTime":"0","endTime":"0","summary":"新锐医药公布截至2026年6月30日止六个月业绩，实现营收约1.13亿港元，同比上涨153.7%。同期经调整净亏损约356.50万港元，相较上一年同期约745.40万港元减少52.2%。经营活动产生的现金流量净额约为0.49亿港元，较上一年同期的净流出显著改善。公司在报告中指出，中国医药行业正面临带量采购政策与药价下行的压力，未来将持续丰富现有产品组合，并继续提高和增强销售及营销能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"新锐医药2026年上半年营收1.13亿港元，经调整净亏损356.50万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113337538","title":"新锐医药二零二五年年报：完善董事会架构与多层级投资风险管控","url":"https://stock-news.laohu8.com/highlight/detail?id=1113337538","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113337538?lang=zh_cn&edition=full","pubTime":"2026-09-04 21:02","pubTimestamp":1788526966,"startTime":"0","endTime":"0","summary":"新锐医药在报告期内进一步强化公司治理与内部控制，董事会、投资委员会及管理层形成多层级组织架构。董事会作为最高决策机构，负责审批投资政策、风险管理框架及年度投资预算，并定期检视财务与营运数据，以确保合规与管理效率。投资委员会主要对重大投资进行审核与评估，并向董事会提出建议；管理层则承担日常监督与财务管理职责，定期提交资金运营与风险管理报告。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"新锐医药二零二五年年报：完善董事会架构与多层级投资风险管控","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122243181","title":"新锐医药更新2026年8月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1122243181","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122243181?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:27","pubTimestamp":1788341242,"startTime":"0","endTime":"0","summary":"新锐医药国际控股有限公司于2026年9月2日公告，截至2026年8月31日，公司注册股本及已发行股份总体保持稳定，未发生新增发行、回购或注销等变化。报告显示，公司于2026年8月底的法定注册股本仍为15,000,000,000股普通股，每股面值0.01港元，合计1.50亿港元，与上月底持平。已发行股本为200,616,665股，库藏股数量为0股，均与上月底相同。本次公告由公司秘书吴日升签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190670243","title":"新锐医药2026年上半年财报：营收1.13亿港元，经调整净亏损356.50万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190670243","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190670243?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:57","pubTimestamp":1787835435,"startTime":"0","endTime":"0","summary":"新锐医药披露2026年上半年财报，报告期内实现营收约1.13亿港元，同比增长153.7%。经调整净亏损约为356.50万港元，较上年同期的约745.40万港元减少52.2%。报告期内，医药及相关产品分销及贸易业务实现营收约1.13亿港元，同比上升161.5%，主要源于医药化学试剂产品销量及注射剂药品销量的提升；提供营销及推广服务收入为81.00万港元，同比下降50.7%，公司解释为重点发展药品分销和贸易板块后相应业务投入结构调整所致。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"新锐医药2026年上半年财报：营收1.13亿港元，经调整净亏损356.50万港元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662700541","title":"新锐医药(06108)发布中期业绩 股东应占亏损净额356.5万港元 同比减少52.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662700541","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662700541?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:52","pubTimestamp":1787835178,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新锐医药 发布截至2026年6月30日止6个月中期业绩，收益1.13亿港元，同比增长153.7%;公司拥有人应占亏损净额356.5万港元，同比减少52.2%;每股基本亏损1.78港仙。尽管收益于期内增加，集团于期内取得亏损净额约356.5万港元，亏损净额减少的主要原因为医药化学试剂产品增加;及于2025年推出注射剂药品产品后药品销量增加。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487362.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1511","06108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194711974","title":"新锐医药（06108）定于8月27日审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1194711974","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194711974?lang=zh_cn&edition=full","pubTime":"2026-08-14 20:41","pubTimestamp":1786711260,"startTime":"0","endTime":"0","summary":"新锐医药（06108）14日公告称，董事会将于2026年8月27日（星期四）召开会议，届时将审议并批准公司及其附属公司截至2026年6月30日止六个月的未经审计中期业绩及有关公告，并讨论是否派付股息（如有）。\\n\\n公告显示，会议决议如获通过，将涉及披露公司2026年中期经营及财务表现，并决定潜在股息派付安排。该公告由董事会主席、行政总裁兼执行董事王秋勤于2026年8月14日在香港签署。\\n\\n截至公告日，公司执行董事包括王秋勤、褚雪平及周湾；独立非执行董事为梁志坚、李倩明及施礼贤。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197178712","title":"新锐医药（06108）调整百慕达注册及股份过户登记总处地址","url":"https://stock-news.laohu8.com/highlight/detail?id=1197178712","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197178712?lang=zh_cn&edition=full","pubTime":"2026-08-03 20:35","pubTimestamp":1785760545,"startTime":"0","endTime":"0","summary":"新锐医药（06108）8月3日晚间公告称，自2026年8月3日起，公司在百慕达的注册办事处及股份过户登记总处将由现址迁至“Richmond House, 12 Par-la-Ville Road, Hamilton HM 08, Bermuda”。\\n\\n公司在香港的股份过户登记分处维持不变，继续由卓佳证券登记有限公司负责，地址为香港夏悫道16号远东金融中心17楼。\\n\\n公告显示，变更地址事宜由公司董事会发布，现任主席兼执行董事为王秋勤。公司董事会成员包括执行董事王秋勤女士、褚雪平先生、周湾女士，以及独立非执行董事梁志坚先生、李倩明女士、施礼贤先生。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192326230","title":"新锐医药更新2026年7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1192326230","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192326230?lang=zh_cn&edition=full","pubTime":"2026-08-03 18:27","pubTimestamp":1785752834,"startTime":"0","endTime":"0","summary":"新锐医药国际控股有限公司于2026年8月3日公布截至2026年7月31日止的证券变动月报表。该报告显示，公司截至报告期末的法定注册股本为15,000,000,000股，面值每股0.01港元，对应总额150,000,000港元。本期法定注册股本与上月一致。本期公司已发行普通股数量为200,616,665股，较上月无增减变动，库存股数量亦保持为0股。本月未发生任何新增发行、回购、注销或库存股份变动。公司表示，将继续严格遵守香港联交所《上市规则》及相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164033788","title":"新锐医药6月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1164033788","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164033788?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:56","pubTimestamp":1782986217,"startTime":"0","endTime":"0","summary":"新锐医药国际控股有限公司于2026年7月2日披露了截至2026年6月30日的证券变动月报表。根据公告，公司本月未进行任何新增发行或股份购回，也不存在股份注销或库藏股变动。公告并确认，所有证券发行及股份变动均经董事会批准，符合香港联交所《上市规则》等相关法规的要求。公司表示将持续遵守香港联交所的各项规定，保持信息披露的透明与合规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159224816","title":"新锐医药2026年5月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1159224816","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159224816?lang=zh_cn&edition=full","pubTime":"2026-06-02 16:42","pubTimestamp":1780389749,"startTime":"0","endTime":"0","summary":"新锐医药国际控股有限公司于2026年6月2日发布截至2026年5月31日的月度股份变动报告。报告显示，该公司本月授权及已发行股本均未发生变化，股本结构持续保持稳定。截至2026年5月31日，已发行股份总数为200,616,665股，与上月持平，未出现新增发行、购回或注销股票的情况，亦未有库藏股变动。公司确认已遵守香港联合交易所有限公司的相关上市规则及适用的法律规定。公告由公司秘书吴日升签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180506252","title":"新锐医药更新2026年4月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1180506252","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180506252?lang=zh_cn&edition=full","pubTime":"2026-05-04 17:17","pubTimestamp":1777886256,"startTime":"0","endTime":"0","summary":"新锐医药于2026年5月4日发布截至2026年4月30日的证券变动月报表。公告显示，公司法定股本总数仍为15,000,000,000股普通股，每股面值为0.01港元，总金额为150,000,000港元，与上月保持一致。已发行股份总数为200,616,665股，无库藏股，公司确认符合主要上市规则有关公众持股量的要求。公司现有一项于2013年10月25日采纳的购股权计划，期末持有购股权数量为12,820,000份，与上月相同，报告期内未有新股发行或购回记录。本次公告由公司秘书吴日升签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145154150","title":"新锐医药授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1145154150","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145154150?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:46","pubTimestamp":1777294000,"startTime":"0","endTime":"0","summary":"新锐医药国际控股有限公司董事会宣布，已向股东提呈普通决议案，以授予董事一般及无条件授权，在股东周年大会通过后，可于香港联交所或其他获准交易所购回公司不超过当日已发行股份总数的10%。本公司提醒股东需留意投票及股份过户登记的具体安排。董事会建议股东审慎行使表决权。根据公告，若该授权顺利获得通过，董事会将在适当情况下行使回购权，以实现为股东创造更大回报的目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"新锐医药授予董事股份购回授权，规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101827026","title":"新锐医药(06108)2025年收入同比增长约38.9%，核心分销业务稳步扩张","url":"https://stock-news.laohu8.com/highlight/detail?id=1101827026","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101827026?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:46","pubTimestamp":1777293990,"startTime":"0","endTime":"0","summary":"新锐医药于2025年度在主营业务方面取得收入约130.37百万港元，相比2024年的93.95百万港元增长约38.9%，带动整体经营规模进一步扩大。医疗及相关产品分销及贸易板块为主要收入来源，推出新产品并在内地市场实施分级分类管理策略，推动该分部收入由88.7百万港元增至127.9百万港元。另一个提供销售及推广服务的板块因部分推广产品挂网下跌或终止销售，全年收入减少超过半数。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"新锐医药(06108)2025年收入同比增长约38.9%，核心分销业务稳步扩张","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514120352","title":"所有产品任职回报均为负，大成基金“新锐医药投资黑马”引质疑","url":"https://stock-news.laohu8.com/highlight/detail?id=2514120352","media":"媒体滚动","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514120352?lang=zh_cn&edition=full","pubTime":"2025-02-28 07:02","pubTimestamp":1740697320,"startTime":"0","endTime":"0","summary":"　　春节后A股持续回暖，但大成基金旗下基金经理邹建管理的多只产品却“逆市亏损”。　　《华夏时报》记者在大成基金官网看到，邹建管理的所有产品的任职回报均为负数。　　针对产品业绩等问题，《华夏时报》记者2月24日联系大成基金客服人员并发送采访函。　　大成基金的官网中有一张基金经理邹建的海报，上面写着“新锐医药投资黑马”的字样。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-02-28/doc-inemysvx0255281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1511","06108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512047146","title":"新锐医药盘中异动 早盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512047146","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512047146?lang=zh_cn&edition=full","pubTime":"2025-02-19 10:43","pubTimestamp":1739933037,"startTime":"0","endTime":"0","summary":"2025年02月19日早盘10时43分，新锐医药股票出现异动，股价大幅上涨5.00%。截至发稿，该股报0.042港元/股，成交量28万股，换手率0.02%，振幅2.50%。新锐医药股票所在的药品分销行业中，整体跌幅为0.37%。其相关个股中，CLSA PREMIUM、新锐医药、阿里健康涨幅较大，振幅较大的相关个股有CLSA PREMIUM、叮当健康、阿里健康，振幅分别为48.65%、11.67%、9.29%。新锐医药公司简介：新锐医药国际控股有限公司是一家主要从事医药产品分销及贸易业务的公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219104357abd44fd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219104357abd44fd5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06108","BK1511"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.newraymedicine.com","stockEarnings":[{"period":"1week","weight":0.055},{"period":"1month","weight":0.0648},{"period":"3month","weight":0.1443},{"period":"6month","weight":0.0748},{"period":"1year","weight":-0.4321},{"period":"ytd","weight":-0.1636}],"compareEarnings":[{"period":"1week","weight":0.0096},{"period":"1month","weight":-0.0215},{"period":"3month","weight":-0.0029},{"period":"6month","weight":-0.0646},{"period":"1year","weight":-0.0768},{"period":"ytd","weight":-0.053}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"新锐医药国际控股有限公司是一家主要从事医药分销贸易以及提供营销和推广服务的投资控股公司。该公司通过两个分部开展业务。医药及相关产品分销及贸易分部主要从事药品及医药化学试剂分销及贸易。提供营销及推广服务分部主要从事提供药品及医药化学试剂的营销及推广服务。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.131615},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.053553},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.062306},{"month":4,"riseRate":0.571429,"avgChangeRate":1.15111},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.127188},{"month":6,"riseRate":0.142857,"avgChangeRate":-0.078607},{"month":7,"riseRate":0,"avgChangeRate":-0.203423},{"month":8,"riseRate":0.25,"avgChangeRate":0.999383},{"month":9,"riseRate":0.375,"avgChangeRate":-0.048901},{"month":10,"riseRate":0.375,"avgChangeRate":-0.042253},{"month":11,"riseRate":0.166667,"avgChangeRate":-0.079375},{"month":12,"riseRate":0.5,"avgChangeRate":-0.006947}],"exchange":"SEHK","name":"新锐医药","nameEN":"NEW RAY MEDIC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"新锐医药(06108)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供新锐医药(06108)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"新锐医药,06108,新锐医药股票,新锐医药股票老虎,新锐医药股票老虎国际,新锐医药行情,新锐医药股票行情,新锐医药股价,新锐医药股市,新锐医药股票价格,新锐医药股票交易,新锐医药股票购买,新锐医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"新锐医药(06108)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供新锐医药(06108)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}